1. Home /
  2. Drug Approvals

Drug Approvals

Nektar Shares Drop After Double Downgrade to Sell at Goldman Sachs

Nektar Shares Drop After Double Downgrade to Sell at Goldman Sachs

Goldman also slashes its one-year price target by nearly two-thirds on expectations that Nektar's in-the-works cancer treatment won't generate revenue anytime soon.

Akcea Shares Sink as Three Top Executives Leave the Biopharma

Akcea Shares Sink as Three Top Executives Leave the Biopharma

Three top executives -- CEO Paula Soteropoulos as well as the president and the COO -- stepped down.

Merck Is Hot. Red Hot. Here's Why

Merck Is Hot. Red Hot. Here's Why

Merck has had a very busy week -- and investment dollars have followed.

FDA Approves Merck, Eisai Treatment for Advanced Endometrial Carcinoma

FDA Approves Merck, Eisai Treatment for Advanced Endometrial Carcinoma

Merck says it's the first combination treatment to receive simultaneous review decisions in the U.S., Australia and Canada.

3 Small Biotechs With Favorable Risk Vs. Reward Profiles

3 Small Biotechs With Favorable Risk Vs. Reward Profiles

BioDelivery Sciences International, Chiasma Inc. and TherapeticsMD all feature promising treatments.

Alder Biopharmaceuticals Surges on Lundbeck Offer

Alder Biopharmaceuticals Surges on Lundbeck Offer

Alder Biopharmaceuticals surges after rival Danish drugmaker Lundbeck announces plans to acquire the company and its late-stage migraine drug eptinezumab in a deal worth up to $1.95 billion.

Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment

Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment

Acadia Pharmaceuticals rockets higher after it announces it has ended a phase 3 trial of its dementia-related psychosis treatment, pimavanserin, on better-than-expected results.

Mallinckrodt Plunges on Report It's Considering Filing for Bankruptcy

Mallinckrodt Plunges on Report It's Considering Filing for Bankruptcy

Shares of drugmaker Mallinckrodt plunge on a report the company is considering filing for bankruptcy as a way of dealing with its opioid-related legal liabilities.

AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer

AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer

Rova-T failed to show a survival benefit for patients when compared with a placebo.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.